Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RESEARCH TOOLSreports
Holding RVPH?
Track your performance easily
RVPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $4.83
Previous CloseN/A
Volume1.63M
Average Volume (3M)4.18M
Market Cap
$88.97M
Enterprise Value$43.20M
Total Cash (Recent Filing)$193.00
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 24, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding46,579,200
10 Day Avg. Volume2,370,153
30 Day Avg. Volume4,176,949
Standard Deviation0.48
R-Squared0.00018
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.39
Forecast
1Y Price Target
$7.00Price Target Upside284.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Reviva Pharmaceuticals Holdings News
PremiumCompany Announcements
Reviva Pharmaceuticals Strengthens Financial Position with Offering
PremiumCompany Announcements
Reviva Pharmaceuticals Reports Positive Phase 3 Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical EfficacyPositive vocal biomarker data was reported from the prior P3 study, indicating brilaroxazine potential to improve negative symptoms of schizophrenia, which remains an unmet need in the space as current therapies target positive symptoms.
Clinical TrialsBrilaroxazine is in a potentially stronger position as it progresses into its second P3 study, following the success of the first P3 which achieved significant results on PANSS scores.
Market PerformanceRVPH shares are up ~30%, thought to be due to the OLE data and recent developments with competitors.
Bears Say
Capital NeedsReviva continues to try and address its capital needs for the second P3 study.
Funding ConstraintsFunding constraints have delayed the P3 launch and management is yet to address capital.
Hold RatingHold rating is maintained as clarity on how the company will address its capital needs to fund the next second P3 'RECOVER-2' study is awaited.
---
Ownership Overview
4.51%
Insiders
2.65% Mutual Funds
0.03% Other Institutional Investors
90.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.60 and its highest was $4.83 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $88.97M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Mar 24, 2025 which is in 53 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Nov 14, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.006.
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -0.22.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 46,579,200 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -7.438%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Among the largest hedge funds holding Reviva Pharmaceuticals Holdings’s share is Woodline Partners LP. It holds Reviva Pharmaceuticals Holdings’s shares valued at 986K.
---
Reviva Pharmaceuticals Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (284.62% Upside)
$7.00 (284.62% Upside)
Blogger Sentiment
Bullish
RVPH Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 908.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.89%
12-Months-Change
Fundamentals
Return on Equity
334.44%
Trailing 12-Months
Asset Growth
41.63%
Trailing 12-Months
Company Description
Reviva Pharmaceuticals Holdings
Tenzing Acquisition Corp. is a blank check company, which engages in the acquisition of similar business combination with one or more businesses and entities. It focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction. The company was founded on March 20, 2018 and is headquartered in New York, NY.
---
RVPH Stock 12 Month Forecast
Average Price Target
$7.00
▲(284.62% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
Viking Therapeutics
―
Xenon
―
Axsome Therapeutics
―
Best Analysts Covering RVPH
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-32.66%
reiterated a buy rating 8 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -32.66% per trade.
---